The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology.
Alzheimer’s disease
Posted inHealth, News
Drug slows Alzheimer’s but can it make a real difference?
New data shows an experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening.
advertisement
Posted inOp-Eds, Opinion
Maine Voices: The long goodbye – my family, my father and Alzheimer’s
The disease’s progression tests our ties, but maybe a cure is in the pipeline so other families will not have to endure what we and many millions of others do each day.
Posted inHealth, Local & State
Gov. Mills launches program to give grants up to $2,000 to family caregivers
The $5.1 million program is for family caregivers of patients with disabilities, such as Alzheimer’s and dementia, who are being cared for at home.
Posted inHealth
Even simple exercise may help aging brain, study hints
Stretching and balancing moves can be as beneficial as an aerobic workout.
Posted inOp-Eds, Opinion
Commentary: The next hospital crisis is coming. Let’s hope the U.S. is prepared
Response teams that respect and protect patients and care providers are one essential solution for behavioral emergencies among people with dementia.
Posted inHealth, Nation & World
Research looks for possible COVID-19 link to later Alzheimer’s
Experts stress far more research is needed – and getting underway – to tell if COVID-19 might raise the risk of Alzheimer’s or other brain problems later in life, or if people eventually recover from ‘brain fog.’
Posted inHealth
FDA chief calls for investigation into review of controversial new Alzheimer’s drug
It’s the latest fallout over last month’s approval of Aduhelm, an expensive and unproven therapy that the agency OK’d against the advice of its own outside experts.
Posted inHealth
FDA reverses itself under pressure, moves to limit use of new Alzheimer’s drug
The Food and Drug Administration says the change is intended to address confusion among physicians and patients about who should get Aduhelm, which has faced an intense public backlash since its approval last month.
Posted inOp-Eds, Opinion
Commentary: Medicare must study unproven, expensive Alzheimer’s drug
Taxpayers and patients cannot afford to pay a high price for a treatment not known to be effective.